Alemtuzumab
Trovati 4 articoli
- Six infection-related deaths reported after treatment with MabCampath following Fludarabine + Rituximab induction in patients with B-cell chronic lymphocytic leukemia
- Genzyme Europe BV has informed Healthcare Professional of six infection-related deaths, reported from a trial ( CALGB10101 ) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia patients were treated with Fludarabine and Rituximab followed by Alemtuzumab for remission co... (Leggi Articolo)
- B-cell chronic lymphocytic leukemia : six infection-related deaths reported after treatment with Fludarabine, Rituximab and Alemtuzumab
- Bayer Schering Pharma AG and Genzyme Europe BV have informed Healthcare Professionals on six infection-related deaths, reported from a trial ( CALGB10101 ) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia patients were treated with Fludarabine ( Fludara ) and Rituxi... (Leggi Articolo)
- MabCampath more effective than Rebif in relapsing-remitting multiple sclerosis
- Two-year interim results from a Phase 2 trial comparing MabCampath ( Alemtuzumab; Campath ) with Rebif ( Interferon beta-1a ) for the treatment of multiple sclerosis have demonstrated statistically significant efficacy of Campath compared to Rebif. The phase 2 trial randomized 334 patients wit... (Leggi Articolo)
- MRD-negative remission with MabCampath improves survival in patients with chronic lymphocytic leucemia
- The 84 percent of patients who had no detectable traces of chronic lymphocytic leukemia ( CLL ) after receiving Alemtuzumab had survived for at least 5 years. A study, led by Peter Hillmen from the Leeds General Infirmary, Leeds ( UK ), evaluated whether eradication of minimal residual disease... (Leggi Articolo)
